Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Immunovant, Inc. (IMVT)
USD38.70
-1.01 (-2.54%)
US NASDAQ Healthcare Biotechnology
Address
320 West 37th Street 10018
New York City, NY, US
New York City, NY, US
CEO
Eric Venker
Website
immunovant.com
IPO
2019-06-21
CIK 1764013 ISIN US45258J1025
Description
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD38.70
-1.01 (-2.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.77
Float Shares
78.82M
Free Float %
38.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.94% | -5.03% | +18.37% | +23.42% | +42.74% | +33.08% | +136.74% | +60.71% | +118.40% | +240.00% | +240.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (23 ratings, all time)
Buy
Price Targets & DCF
Current price
38.70
Low
40.00
+3.4%
Consensus
43.67
+12.8%
Median
41.00
+5.9%
High
50.00
+29.2%
DCF (Unlevered)
4.93
-87.3%
DCF (Levered)
4.94
-87.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
72% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 11 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
40.00
+3.4%
|
| Last Quarter | 1 |
40.00
+3.4%
|
| Last Year | 4 |
36.75
-5.0%
|
| All Time | 10 |
40.40
+4.4%
|
Quality scores
Altman Z-Score
36.97
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-1.5% Q1'26: -14.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,266.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.4% Q1'26: +34.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Mar 2025 actual |
Mar 2026 8 Rev. Ana. 11 EPS Ana. |
Mar 2027 10 Rev. Ana. 9 EPS Ana. |
Mar 2028 11 Rev. Ana. 9 EPS Ana. |
Mar 2029 10 Rev. Ana. 9 EPS Ana. |
Mar 2030 5 Rev. Ana. 3 EPS Ana. |
Mar 2031 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 30.10M (-100.0%)
|
10.49M
7.24M – 15.13M
-65.1% YoY
|
6.64M
4.59M – 9.58M
-36.7% YoY
|
85.29M
35.17M – 156.81M
+1,183.6% YoY
|
450.42M
310.92M – 649.51M
+428.1% YoY
|
1.02B
704.40M – 1.47B
+126.6% YoY
|
1.57B
1.08B – 2.26B
+53.4% YoY
|
| EBITDA |
-437.78M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-438.15M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-413.84M
est: -447.30M (+7.5%)
|
-505.61M
-519.27M – -453.24M
-13.0% YoY
|
-535.29M
-547.45M – -394.88M
-5.9% YoY
|
-446.70M
-492.35M – -401.04M
+16.6% YoY
|
-317.98M
-587.78M – 30.93M
+28.8% YoY
|
98.96M
59.12M – 155.83M
+131.1% YoY
|
409.84M
244.83M – 645.33M
+314.1% YoY
|
| SGA |
77.24M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.73
est: -2.81 (+2.7%)
|
-2.61
-2.85 – -2.48
+7.0% YoY
|
-2.58
-3.00 – -2.16
+1.3% YoY
|
-2.52
-2.70 – -2.20
+2.2% YoY
|
-1.50
-3.22 – 0.17
+40.7% YoY
|
0.54
0.32 – 0.85
+136.3% YoY
|
2.25
1.34 – 3.54
+314.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-22 | Truist Securities | Hold | Hold | Maintain |
| 2026-05-21 | B of A Securities | Buy | Buy | Maintain |
| 2026-04-15 | Goldman Sachs | Neutral | Neutral | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
226
Total invested
2.75B
Insider transactions (90d)
5
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Roivant Sciences Ltd. | 79.82M | 55.30% | 79.82M | — | 79.82M | — | CO | — | 2023-10-04 | ↗ |
| 2 | Abigail P. Johnson | 7.88M | 5.44% | — | — | 7.88M | — | IN | United States of America | 2024-02-09 | ↗ |
| 3 | FMR LLC | 7.88M | 5.44% | 7.87M | — | 7.88M | — | HC | Delaware | 2024-02-09 | ↗ |
| 4 | RTW Investments, LP | 7.59M | 7.75% | — | 7.59M | — | 7.59M | IA, PN, OO | Cayman Islands | 2021-02-16 | ↗ |
| 5 | Roderick Wong | 7.59M | 7.75% | — | 7.59M | — | 7.59M | HC, IN | Cayman Islands | 2021-02-16 | ↗ |
| 6 | David Kroin | 6.78M | 5.83% | — | 6.78M | — | — | HC, IN | United States | 2022-02-11 | ↗ |
| 7 | Deep Track Biotechnology Master Fund, Ltd. | 6.78M | 5.83% | — | 6.78M | — | — | CO | Cayman Islands | 2022-02-11 | ↗ |
| 8 | Deep Track Capital, LP | 6.78M | 5.83% | — | 6.78M | — | — | IA, OO | Delaware | 2022-02-11 | ↗ |
| 9 | RTW Master Fund, Ltd. | 5.30M | 5.41% | — | 5.30M | — | 5.30M | CO | Cayman Islands | 2021-02-16 | ↗ |
| 10 | Roderick Wong, M.D. | 4.43M | 7.80% | 4.43M | — | 4.43M | 10.00 | IN | United States | 2019-12-27 | ↗ |
| 11 | Bihua Chen | 1.08M | 7.51% | — | 1.08M | — | — | IN | United States | 2019-05-20 | ↗ |
| 12 | Cormorant Asset Management, LP | 1.08M | 7.51% | — | 1.08M | — | — | PN | Delaware | 2019-05-20 | ↗ |
| 13 | Adage Capital Advisors, L.L.C. | 1.02M | 7.10% | — | 1.02M | — | — | OO | Delaware | 2019-05-20 | ↗ |
| 14 | Adage Capital Partners GP, L.L.C. | 1.02M | 7.10% | — | 1.02M | — | — | OO | Delaware | 2019-05-20 | ↗ |
| 15 | Adage Capital Partners, L.P. | 1.02M | 7.10% | — | 1.02M | — | — | PN | Delaware | 2019-05-20 | ↗ |
| 16 | Phillip Gross | 1.02M | 7.10% | — | 1.02M | — | — | IN | United States | 2019-05-20 | ↗ |
| 17 | Robert Atchinson | 1.02M | 7.10% | — | 1.02M | — | — | IN | United States | 2019-05-20 | ↗ |
| 18 | Cormorant Private Healthcare Fund II, LP | 842.0K | 5.86% | — | 842.0K | — | — | PN | Delaware | 2019-05-20 | ↗ |
| 19 | Cormorant Private Healthcare GP II, LLC | 842.0K | 5.86% | — | 842.0K | — | — | OO | Delaware | 2019-05-20 | ↗ |
| 20 | Cormorant Global Healthcare GP, LLC | 215.9K | 1.50% | — | 215.9K | — | — | OO | Delaware | 2019-05-20 | ↗ |
| 21 | Cormorant Global Healthcare Master Fund, LP | 215.9K | 1.50% | — | 215.9K | — | — | PN | Cayman Islands | 2019-05-20 | ↗ |
| 22 | Absolute Return Strategies LP | — | 0.00% | — | — | — | — | PN | Delaware | 2020-02-12 | ↗ |
| 23 | Fund Management, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2020-02-12 | ↗ |
| 24 | Glass | — | 0.00% | — | — | — | — | HC | States | 2020-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
226
+18 vs prev Q
New positions
44
Closed positions
26
Increased
139
Reduced
41
Put/Call ratio
0.10
Calls held
2.51M
Puts held
262.8K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 240.2K +240.2K (+100.0%) | 6.10B +6.1B (+100.0%) | 0.13% +0.132 pp | 1.51% +1.508 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 122.1K +122.1K (+100.0%) | 3.10B +3.1B (+100.0%) | 0.07% +0.067 pp | 0.00% +0.005 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 3 | FMR LLC | 16.99M +2.3M (+15.4%) | 431.90M +194.5M (+81.9%) | 9.36% +0.740 pp | 0.02% +0.010 pp | USD23.40 +8.6% | 16 qtrs — |
| 4 | DEEP TRACK CAPITAL, LP | 11.53M +1.8M (+18.5%) | 293.02M +136.2M (+86.8%) | 6.35% +0.657 pp | 5.22% +0.848 pp | USD22.63 +12.3% | 17 qtrs — |
| 5 | VANGUARD GROUP INC | 7.78M +952.5K (+14.0%) | 197.75M +87.7M (+79.7%) | 4.29% +0.291 pp | 0.00% +0.001 pp | USD27.53 -7.7% | 23 qtrs — |
| 6 | BLACKROCK, INC. | 6.06M +320.0K (+5.6%) | 154.00M +61.5M (+66.5%) | 3.34% -0.021 pp | 0.00% +0.001 pp | USD26.90 -5.5% | 6 qtrs — |
| 7 | BAKER BROS. ADVISORS LP | 5.46M +— (+0.0%) | 138.74M +50.8M (+57.7%) | 3.01% -0.187 pp | 0.81% +0.177 pp | USD21.10 +20.5% | 10 qtrs — |
| 8 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 5.06M -104.3K (-2.0%) | 128.64M +45.4M (+54.5%) | 2.79% -0.235 pp | 0.08% +0.030 pp | USD24.22 +5.0% | 7 qtrs — |
| 9 | MORGAN STANLEY | 4.85M +2.9M (+147.4%) | 123.20M +91.6M (+290.1%) | 2.67% +1.524 pp | 0.01% +0.005 pp | USD23.79 +6.9% | 25 qtrs — |
| 10 | STATE STREET CORP | 3.79M +894.3K (+30.9%) | 96.26M +49.6M (+106.4%) | 2.09% +0.394 pp | 0.00% +0.002 pp | USD22.17 +14.7% | 23 qtrs — |
| 11 | RTW INVESTMENTS, LP | 3.18M +3.2M (+100.0%) | 80.78M +80.8M (+100.0%) | 1.75% +1.751 pp | 0.81% +0.809 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 12 | TWO SEAS CAPITAL LP | 2.87M +104.9K (+3.8%) | 72.88M +28.4M (+63.7%) | 1.58% -0.037 pp | 1.50% +0.787 pp | USD22.90 +11.0% | 10 qtrs — |
| 13 | ALPINE GLOBAL MANAGEMENT, LLC | 2.63M -128.0K (-4.6%) | 66.77M +22.4M (+50.4%) | 1.51% -0.100 pp | 12.04% +4.096 pp | USD18.39 +38.2% | 20 qtrs — |
| 14 | ADAR1 CAPITAL MANAGEMENT, LLC | 2.48M +239.2K (+10.7%) | 63.07M +26.9M (+74.5%) | 1.43% +0.117 pp | 4.63% +1.237 pp | USD19.29 +31.8% | 9 qtrs — |
| 15 | POINT72 ASSET MANAGEMENT, L.P. | 2.00M -1.4M (-41.9%) | 50.84M -4.6M (-8.4%) | 1.10% -0.913 pp | 0.06% -0.036 pp | USD16.26 +56.3% | 4 qtrs — |
| 16 | PERCEPTIVE ADVISORS LLC | 1.99M +407.0K (+25.6%) | 50.71M +25.1M (+98.1%) | 1.10% +0.170 pp | 0.90% +0.165 pp | USD24.41 +4.1% | 13 qtrs — |
| 17 | WOODLINE PARTNERS LP | 1.98M +477.1K (+31.8%) | 50.23M +26.1M (+107.9%) | 1.09% +0.212 pp | 0.19% +0.081 pp | USD22.37 +13.6% | 15 qtrs — |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 1.86M +55.9K (+3.1%) | 47.23M +18.2M (+62.6%) | 1.02% -0.031 pp | 0.00% +0.001 pp | USD25.83 -1.6% | 24 qtrs — |
| 19 | TCG CROSSOVER MANAGEMENT, LLC | 1.66M +1.7M (+100.0%) | 42.22M +42.2M (+100.0%) | 0.92% +0.915 pp | 1.40% +1.397 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 20 | LOGOS GLOBAL MANAGEMENT LP | 1.38M +1.1M (+400.0%) | 34.95M +30.5M (+688.5%) | 0.76% +0.597 pp | 2.11% +1.715 pp | USD25.38 +0.2% | 13 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 1.30M -186.5K (-12.6%) | 32.94M +9.0M (+37.9%) | 0.75% -0.121 pp | 0.00% +0.001 pp | USD20.74 +22.6% | 24 qtrs — |
| 22 | ABRDN PLC | 1.18M +202.3K (+20.6%) | 30.10M +14.3M (+90.2%) | 0.68% +0.107 pp | 0.05% +0.022 pp | USD25.32 +0.4% | 9 qtrs — |
| 23 | SOLEUS CAPITAL MANAGEMENT, L.P. | 1.11M +1.1M (+100.0%) | 28.22M +28.2M (+100.0%) | 0.61% +0.612 pp | 1.04% +1.041 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 24 | PRICE T ROWE ASSOCIATES INC /MD/ | 893.1K +688.5K (+336.5%) | 22.70M +19.4M (+588.2%) | 0.49% +0.372 pp | 0.00% +0.002 pp | USD24.85 +2.3% | 13 qtrs — |
| 25 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 863.0K +519.4K (+151.2%) | 21.94M +16.4M (+296.1%) | 0.48% +0.274 pp | 0.03% +0.024 pp | USD21.94 +15.9% | 10 qtrs — |
| 26 | GREAT POINT PARTNERS LLC | 750.0K +250.0K (+50.0%) | 19.07M +11.0M (+136.5%) | 0.41% +0.121 pp | 6.18% +2.858 pp | USD19.56 +30.0% | 4 qtrs — |
| 27 | ARMISTICE CAPITAL, LLC | 750.0K +750.0K (+100.0%) | 19.07M +19.1M (+100.0%) | 0.41% +0.413 pp | 0.23% +0.227 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 28 | UBS GROUP AG | 732.4K +6.2K (+0.9%) | 18.62M +6.9M (+59.0%) | 0.40% -0.022 pp | 0.00% +0.001 pp | USD23.54 +8.0% | 25 qtrs — |
| 29 | JENNISON ASSOCIATES LLC | 700.5K +700.5K (+100.0%) | 17.81M +17.8M (+100.0%) | 0.40% +0.403 pp | 0.01% +0.011 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 30 | CANDRIAM S.C.A. | 680.4K +680.4K (+100.0%) | 17.30M +17.3M (+100.0%) | 0.37% +0.375 pp | 0.09% +0.086 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 31 | STEMPOINT CAPITAL LP | 645.0K -944.6K (-59.4%) | 16.39M -9.2M (-36.0%) | 0.36% -0.575 pp | 2.81% -2.323 pp | USD23.51 +8.1% | 9 qtrs — |
| 32 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 643.0K +62.3K (+10.7%) | 16.34M +7.0M (+74.6%) | 0.35% +0.014 pp | 0.00% +0.001 pp | USD25.63 -0.8% | 23 qtrs — |
| 33 | NORTHERN TRUST CORP | 566.1K +10.2K (+1.8%) | 14.39M +5.4M (+60.6%) | 0.31% -0.013 pp | 0.00% +0.001 pp | USD25.76 -1.3% | 25 qtrs — |
| 34 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 467.5K -91.4K (-16.4%) | 11.88M +2.9M (+31.9%) | 0.26% -0.070 pp | 0.03% +0.003 pp | USD20.42 +24.5% | 18 qtrs — |
| 35 | PICTET ASSET MANAGEMENT HOLDING SA | 380.8K -295.7K (-43.7%) | 9.68M -1.2M (-11.2%) | 0.22% -0.177 pp | 0.01% -0.001 pp | USD38.18 -33.4% | 10 qtrs — |
| 36 | BNP PARIBAS ARBITRAGE, SNC | 353.1K -330.3K (-48.3%) | 8.97M -2.0M (-18.5%) | 0.19% -0.205 pp | 0.00% -0.002 pp | USD17.22 +47.6% | 5 qtrs — |
| 37 | BANK OF AMERICA CORP /DE/ | 313.5K -61.3K (-16.4%) | 7.97M +1.9M (+31.9%) | 0.17% -0.047 pp | 0.00% +0.000 pp | USD25.78 -1.4% | 24 qtrs — |
| 38 | SUPERSTRING CAPITAL MANAGEMENT LP | 288.7K -52.7K (-15.4%) | 7.34M +1.8M (+33.4%) | 0.16% -0.041 pp | 3.93% -1.492 pp | USD16.12 +57.7% | 2 qtrs — |
| 39 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 259.1K +14.9K (+6.1%) | 6.59M +2.6M (+67.3%) | 0.14% 0.000 pp | 0.00% +0.000 pp | USD21.95 +15.8% | 22 qtrs — |
| 40 | PROSIGHT MANAGEMENT, LP | 243.4K -455.1K (-65.2%) | 6.19M -5.1M (-45.0%) | 0.13% -0.275 pp | 1.28% -1.347 pp | USD22.16 +14.7% | 8 qtrs — |
| 41 | BARCLAYS PLC | 232.3K +14.5K (+6.7%) | 5.91M -304.1K (-4.9%) | 0.13% +0.001 pp | 0.00% 0.000 pp | USD24.47 +3.9% | 14 qtrs — |
| 42 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 230.2K -36.0K (-13.5%) | 5.85M +1.6M (+36.3%) | 0.13% -0.029 pp | 0.25% +0.075 pp | USD21.04 +20.8% | 5 qtrs — |
| 43 | NUVEEN, LLC | 226.5K +1.4K (+0.6%) | 5.76M +2.1M (+58.7%) | 0.12% -0.007 pp | 0.00% +0.001 pp | USD17.14 +48.3% | 4 qtrs — |
| 44 | TD ASSET MANAGEMENT INC | 225.0K +89.2K (+65.7%) | 5.72M +3.5M (+161.3%) | 0.12% +0.045 pp | 0.00% +0.003 pp | USD26.35 -3.5% | 13 qtrs — |
| 45 | HIGHVISTA STRATEGIES LLC | 221.9K -31.2K (-12.3%) | 5.64M +1.6M (+38.2%) | 0.12% -0.026 pp | 1.45% +0.452 pp | USD16.45 +54.5% | 4 qtrs — |
| 46 | ASSENAGON ASSET MANAGEMENT S.A. | 205.2K +— (+0.0%) | 5.22M +1.9M (+57.7%) | 0.12% -0.002 pp | 0.01% +0.003 pp | USD16.12 +57.7% | 2 qtrs — |
| 47 | AFFINITY ASSET ADVISORS, LLC | 200.0K -100.0K (-33.3%) | 5.08M +248.0K (+5.1%) | 0.11% -0.065 pp | 0.29% -0.132 pp | USD16.12 +57.7% | 11 qtrs — |
| 48 | BANK OF NEW YORK MELLON CORP | 199.4K -2.6K (-1.3%) | 5.07M +1.8M (+55.7%) | 0.11% -0.008 pp | 0.00% +0.000 pp | USD28.11 -9.6% | 23 qtrs — |
| 49 | PLATINUM INVESTMENT MANAGEMENT LTD | 181.8K -14.0K (-7.1%) | 4.62M +1.5M (+46.5%) | 0.10% -0.014 pp | 1.07% +0.864 pp | USD10.57 +140.5% | 18 qtrs — |
| 50 | MILLENNIUM MANAGEMENT LLC | 172.5K +84.4K (+95.8%) | 4.38M +3.0M (+208.7%) | 0.10% +0.044 pp | 0.00% +0.001 pp | USD22.82 +11.4% | 24 qtrs — |
| 51 | TFG ASSET MANAGEMENT GP LTD | 166.2K -22.2K (-11.8%) | 4.22M +1.2M (+39.1%) | 0.09% -0.019 pp | 0.89% +0.485 pp | USD16.78 +51.5% | 4 qtrs — |
| 52 | DIMENSIONAL FUND ADVISORS LP | 160.4K -213.8K (-57.1%) | 4.08M -2.0M (-32.4%) | 0.09% -0.131 pp | 0.00% 0.000 pp | USD11.04 +130.3% | 18 qtrs — |
| 53 | EXOME ASSET MANAGEMENT LLC | 158.6K +— (+0.0%) | 4.03M +1.5M (+57.7%) | 0.09% -0.005 pp | 1.93% +0.380 pp | USD16.12 +57.7% | 2 qtrs — |
| 54 | SWISS NATIONAL BANK | 158.3K +25.7K (+19.4%) | 4.02M +1.9M (+88.3%) | 0.09% +0.010 pp | 0.00% +0.001 pp | USD23.20 +9.6% | 23 qtrs — |
| 55 | DAFNA CAPITAL MANAGEMENT LLC | 150.5K -41.0K (-21.4%) | 3.83M +739.5K (+24.0%) | 0.08% -0.029 pp | 0.89% +0.126 pp | USD23.99 +6.0% | 10 qtrs — |
| 56 | JANE STREET GROUP, LLC | 139.2K +59.6K (+74.9%) | 3.54M +2.3M (+175.8%) | 0.08% +0.034 pp | 0.00% +0.000 pp | USD22.47 +13.1% | 6 qtrs — |
| 57 | UBS ASSET MANAGEMENT AMERICAS INC | 134.4K +27.2K (+25.4%) | 3.42M +1.7M (+97.7%) | 0.07% +0.011 pp | 0.00% +0.000 pp | USD28.03 -9.3% | 23 qtrs — |
| 58 | RAFFERTY ASSET MANAGEMENT, LLC | 132.3K +30.5K (+29.9%) | 3.36M +1.7M (+104.9%) | 0.07% +0.013 pp | 0.01% +0.006 pp | USD22.91 +11.0% | 13 qtrs — |
| 59 | ERSTE ASSET MANAGEMENT GMBH | 128.5K +76.0K (+144.8%) | 3.29M +2.4M (+290.3%) | 0.07% +0.040 pp | 0.03% +0.020 pp | USD31.51 -19.3% | 9 qtrs — |
| 60 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 126.6K +126.6K (+100.0%) | 3.22M +3.2M (+100.0%) | 0.07% +0.070 pp | 0.03% +0.025 pp | USD25.42 +0.0% | 19 qtrs — |
| 61 | TREXQUANT INVESTMENT LP | 115.0K +115.0K (+100.0%) | 2.92M +2.9M (+100.0%) | 0.06% +0.063 pp | 0.03% +0.026 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 62 | BANQUE PICTET & CIE SA | 114.9K +993.0 (+0.9%) | 2.92M +1.1M (+59.1%) | 0.07% -0.001 pp | 0.02% +0.007 pp | USD34.05 -25.3% | 9 qtrs — |
| 63 | JUMP FINANCIAL, LLC | 104.6K -191.7K (-64.7%) | 2.66M -2.1M (-44.3%) | 0.06% -0.116 pp | 0.03% -0.025 pp | USD21.10 +20.5% | 12 qtrs — |
| 64 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 97.2K +61.3K (+170.9%) | 2.47M +1.9M (+326.4%) | 0.05% +0.033 pp | 0.00% +0.002 pp | USD27.20 -6.5% | 13 qtrs — |
| 65 | LEGAL & GENERAL GROUP PLC | 92.7K +5.6K (+6.5%) | 2.36M +953.1K (+67.9%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD20.22 +25.7% | 23 qtrs — |
| 66 | ALLIANCEBERNSTEIN L.P. | 89.2K -463.0 (-0.5%) | 2.27M +821.7K (+56.9%) | 0.05% -0.003 pp | 0.00% +0.000 pp | USD18.15 +40.1% | 24 qtrs — |
| 67 | INVESCO LTD. | 88.9K +12.3K (+16.0%) | 2.26M +1.0M (+82.9%) | 0.05% +0.004 pp | 0.00% +0.000 pp | USD31.14 -18.4% | 23 qtrs — |
| 68 | RHUMBLINE ADVISERS | 86.8K -12.1K (-12.3%) | 2.21M +612.2K (+38.4%) | 0.05% -0.010 pp | 0.00% +0.001 pp | USD21.56 +17.9% | 23 qtrs — |
| 69 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 86.0K +21.4K (+33.1%) | 2.18M +1.1M (+109.9%) | 0.05% +0.010 pp | 0.00% +0.001 pp | USD23.76 +7.0% | 23 qtrs — |
| 70 | HRT FINANCIAL LP | 84.8K +84.8K (+100.0%) | 2.16M +2.2M (+100.0%) | 0.05% +0.047 pp | 0.01% +0.007 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 71 | VERITION FUND MANAGEMENT LLC | 80.8K -108.6K (-57.3%) | 2.05M -999.3K (-32.7%) | 0.04% -0.066 pp | 0.01% -0.005 pp | USD16.72 +52.0% | 8 qtrs — |
| 72 | JPMORGAN CHASE & CO | 79.9K +4.5K (+6.0%) | 2.03M +815.9K (+67.2%) | 0.05% +0.002 pp | 0.00% +0.000 pp | USD23.92 +6.3% | 24 qtrs — |
| 73 | BLACKSTONE INC. | 79.7K +79.7K (+100.0%) | 2.03M +2.0M (+100.0%) | 0.04% +0.044 pp | 0.01% +0.008 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 74 | WELLS FARGO & COMPANY/MN | 79.7K +34.7K (+77.3%) | 2.03M +1.3M (+179.6%) | 0.04% +0.018 pp | 0.00% +0.000 pp | USD21.58 +17.8% | 23 qtrs — |
| 75 | HENNION & WALSH ASSET MANAGEMENT, INC. | 71.7K +71.7K (+100.0%) | 1.82M +1.8M (+100.0%) | 0.04% +0.041 pp | 0.06% +0.063 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 76 | ARROWMARK COLORADO HOLDINGS LLC | 70.0K +— (+0.0%) | 1.78M +651.0K (+57.7%) | 0.04% -0.002 pp | 0.04% +0.018 pp | USD38.39 -33.8% | 10 qtrs — |
| 77 | AMUNDI | 67.4K +67.4K (+100.0%) | 1.71M +1.7M (+100.0%) | 0.04% +0.037 pp | 0.00% +0.001 pp | USD25.42 +0.0% | 1 qtrs NEW |
| 78 | DEUTSCHE BANK AG\ | 62.5K +7.7K (+14.0%) | 1.59M +704.5K (+79.8%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD23.60 +7.7% | 23 qtrs — |
| 79 | QUINN OPPORTUNITY PARTNERS LLC | 61.1K +— (+0.0%) | 1.55M +568.3K (+57.7%) | 0.03% -0.002 pp | 0.07% -0.004 pp | USD16.65 +52.7% | 4 qtrs — |
| 80 | CITADEL ADVISORS LLC | 58.8K -31.8K (-35.1%) | 1.49M +34.2K (+2.3%) | 0.03% -0.021 pp | 0.00% +0.000 pp | USD25.06 +1.4% | 13 qtrs — |
| 81 | VOYA INVESTMENT MANAGEMENT LLC | 53.6K +41.0K (+323.9%) | 1.36M +1.2M (+568.5%) | 0.03% +0.022 pp | 0.00% +0.001 pp | USD28.14 -9.7% | 22 qtrs — |
| 82 | PROFUND ADVISORS LLC | 49.1K +26.8K (+120.4%) | 1.25M +888.6K (+247.6%) | 0.03% +0.015 pp | 0.04% +0.026 pp | USD23.02 +10.4% | 12 qtrs — |
| 83 | SIMPLEX TRADING, LLC | 48.4K +33.5K (+224.2%) | 1.23M +990.6K (+412.8%) | 0.03% +0.018 pp | 0.00% +0.001 pp | USD22.54 +12.8% | 14 qtrs — |
| 84 | SG AMERICAS SECURITIES, LLC | 45.6K -17.0K (-27.1%) | 1.16M +151.0K (+15.0%) | 0.03% -0.010 pp | 0.00% -0.002 pp | USD16.10 +57.9% | 3 qtrs — |
| 85 | GSA CAPITAL PARTNERS LLP | 44.1K +17.0K (+62.6%) | 1.12M +684.0K (+156.2%) | 0.02% +0.008 pp | 0.10% +0.060 pp | USD19.70 +29.0% | 2 qtrs — |
| 86 | PRELUDE CAPITAL MANAGEMENT, LLC | 41.7K +— (+0.0%) | 1.06M +387.7K (+57.7%) | 0.02% -0.001 pp | 0.08% +0.026 pp | USD16.12 +57.7% | 2 qtrs — |
| 87 | CREATIVE PLANNING | 41.5K +3.0K (+7.8%) | 1.05M +434.3K (+70.0%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD19.88 +27.9% | 5 qtrs — |
| 88 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 40.3K +3.4K (+9.1%) | 1.02M +428.7K (+72.0%) | 0.02% +0.001 pp | 0.00% +0.001 pp | USD26.28 -3.3% | 7 qtrs — |
| 89 | METLIFE INVESTMENT MANAGEMENT, LLC | 39.0K -1.9K (-4.6%) | 992.3K +333.0K (+50.5%) | 0.02% -0.002 pp | 0.00% +0.002 pp | USD12.85 +97.8% | 23 qtrs — |
| 90 | STATE OF WISCONSIN INVESTMENT BOARD | 38.9K -12.3K (-24.0%) | 989.3K +163.3K (+19.8%) | 0.02% -0.009 pp | 0.00% +0.000 pp | USD17.49 +45.3% | 22 qtrs — |
| 91 | TUDOR INVESTMENT CORP ET AL | 35.9K -4.5K (-11.1%) | 912.6K +261.3K (+40.1%) | 0.02% -0.004 pp | 0.00% +0.001 pp | USD16.12 +57.7% | 2 qtrs — |
| 92 | INTECH INVESTMENT MANAGEMENT LLC | 35.2K +4.0K (+13.0%) | 894.5K +392.4K (+78.1%) | 0.02% +0.001 pp | 0.01% +0.004 pp | USD24.27 +4.7% | 6 qtrs — |
| 93 | JANUS HENDERSON GROUP PLC | 33.7K +3.0K (+9.8%) | 857.3K +361.4K (+72.9%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD26.02 -2.3% | 12 qtrs — |
| 94 | HIGHTOWER ADVISORS, LLC | 33.4K +— (+0.0%) | 849.2K +310.7K (+57.7%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD15.86 +60.3% | 17 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.50
Neutral
Ratio by volume
2.46
Bullish
Buys
24
Sells
16
Shares acquired
1.94M
Shares disposed
788.1K
Cash buys
—
Cash sales
13.00
Net activity
+1,150,830
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Pande Atul | Director | M-Exempt | D | Stock Option (right to buy) | 6,000 | 8.43 | 50.6K | 270,252 | D | ↗ |
| 2026-05-20 | Gloria Melanie | Officer | S-Sale | D | Common Stock | 249 | 30.41 | 7.6K | 244,973 | D | ↗ |
| 2026-05-01 | Susman Robert Graham | Director | S-Sale | D | Common Stock | 2,502 | 27.17 | 68.0K | 36,394 | D | ↗ |
| 2026-04-23 | Stout Jay S | Officer | S-Sale | D | Common Stock | 2,754 | 29.62 | 81.6K | 251,685 | D | ↗ |
| 2026-04-23 | Girao Tiago | Officer | S-Sale | D | Common Stock | 25,760 | 29.62 | 763.0K | 247,596 | D | ↗ |
| 2026-04-08 | Van Tuyl Christopher | Officer | S-Sale | D | Common Stock | 5,165 | 24.83 | 128.2K | 183,231 | D | ↗ |
| 2026-04-08 | Stout Jay S | Officer | S-Sale | D | Common Stock | 1,518 | 24.83 | 37.7K | 254,439 | D | ↗ |
| 2026-04-08 | Gloria Melanie | Officer | S-Sale | D | Common Stock | 8,722 | 24.83 | 216.6K | 245,222 | D | ↗ |
| 2026-04-07 | Venker Eric | Director / Officer | A-Award | A | Common Stock | 232,252 | 0.00 | — | 251,813 | D | ↗ |
| 2026-04-07 | Van Tuyl Christopher | Officer | A-Award | A | Stock Option (right to buy) | 59,820 | 24.61 | 1.47M | 59,820 | D | ↗ |
| 2026-04-07 | Torti Frank | Director | A-Award | A | Common Stock | 174,189 | 0.00 | — | 1,009,228 | D | ↗ |
| 2026-04-07 | Susman Robert Graham | Director | A-Award | A | Common Stock | 13,880 | 0.00 | — | 38,896 | D | ↗ |
| 2026-04-07 | Stout Jay S | Officer | A-Award | A | Stock Option (right to buy) | 96,851 | 24.61 | 2.38M | 96,851 | D | ↗ |
| 2026-04-07 | Pande Atul | Director | A-Award | A | Common Stock | 13,880 | 0.00 | — | 116,731 | D | ↗ |
| 2026-04-07 | Hughes Douglas J. | Director | A-Award | A | Common Stock | 13,880 | 0.00 | — | 134,653 | D | ↗ |
| 2026-04-07 | Gloria Melanie | Officer | A-Award | A | Stock Option (right to buy) | 121,063 | 24.61 | 2.98M | 121,063 | D | ↗ |
| 2026-04-07 | Girao Tiago | Officer | A-Award | A | Stock Option (right to buy) | 94,002 | 24.61 | 2.31M | 94,002 | D | ↗ |
| 2026-04-07 | Fromkin Andrew J. | Director | A-Award | A | Stock Option (right to buy) | 7,061 | 24.61 | 173.8K | 7,061 | D | ↗ |
| 2026-04-07 | Bauer Jake | Director | A-Award | A | Stock Option (right to buy) | 7,061 | 24.61 | 173.8K | 7,061 | D | ↗ |
| 2026-04-02 | Venker Eric | Director / Officer | S-Sale | D | Common Stock | 12,820 | 24.04 | 308.2K | 20,970 | D | ↗ |
| 2026-04-01 | Venker Eric | Director / Officer | M-Exempt | D | Capped Value Appreciation Rights | 368,750 | 14.46 | 5.33M | 1,106,250 | D | ↗ |
| 2026-03-18 | Van Tuyl Christopher | Officer | S-Sale | D | Common Stock | 2,877 | 24.97 | 71.8K | 147,053 | D | ↗ |
| 2026-02-25 | Gloria Melanie | Officer | S-Sale | D | Common Stock | 859 | 28.16 | 24.2K | 171,215 | D | ↗ |
| 2026-01-21 | Stout Jay S | Officer | S-Sale | D | Common Stock | 1,977 | 26.03 | 51.5K | 197,634 | D | ↗ |
| 2026-01-07 | Stout Jay S | Officer | S-Sale | D | Common Stock | 1,148 | 26.51 | 30.4K | 199,666 | D | ↗ |
| 2025-12-18 | Van Tuyl Christopher | Officer | S-Sale | D | Common Stock | 8,529 | 26.78 | 228.4K | 152,214 | D | ↗ |
| 2025-12-12 | Roivant Sciences Ltd. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 16,666,666 | 21.00 | 350.00M | 113,317,007 | D | ↗ |
| 2025-12-01 | Hughes Douglas J. | Director | S-Sale | D | Common Stock | 1,909 | 23.96 | 45.7K | 120,773 | D | ↗ |
| 2025-12-01 | Fromkin Andrew J. | Director | S-Sale | D | Common Stock | 2,898 | 23.95 | 69.4K | 85,852 | D | ↗ |
| 2025-11-20 | Gloria Melanie | Officer | S-Sale | D | Common Stock | 10,251 | 23.54 | 241.3K | 175,886 | D | ↗ |
| 2025-10-22 | Stout Jay S | Officer | S-Sale | D | Common Stock | 2,520 | 19.03 | 48.0K | 200,814 | D | ↗ |
| 2025-10-22 | Geffner Michael | Officer | S-Sale | D | Common Stock | 2,595 | 19.03 | 49.4K | 217,958 | D | ↗ |
| 2025-10-08 | Stout Jay S | Officer | S-Sale | D | Common Stock | 1,585 | 16.30 | 25.8K | 203,334 | D | ↗ |
| 2025-10-08 | Geffner Michael | Officer | S-Sale | D | Common Stock | 1,272 | 16.30 | 20.7K | 220,553 | D | ↗ |
| 2025-07-28 | Venker Eric | Director / Officer | A-Award | A | Capped Value Appreciation Rights | 1,475,000 | 14.46 | 21.33M | 1,475,000 | D | ↗ |
| 2025-07-23 | Stout Jay S | Officer | S-Sale | D | Common Stock | 2,805 | 18.15 | 50.9K | 204,919 | D | ↗ |
| 2025-07-23 | Geffner Michael | Officer | S-Sale | D | Common Stock | 2,385 | 18.15 | 43.3K | 221,825 | D | ↗ |
| 2025-07-09 | Stout Jay S | Officer | S-Sale | D | Common Stock | 1,519 | 17.24 | 26.2K | 207,724 | D | ↗ |
| 2025-07-09 | Geffner Michael | Officer | S-Sale | D | Common Stock | 1,160 | 17.24 | 20.0K | 224,210 | D | ↗ |
| 2025-05-01 | Susman Robert Graham | Director | A-Award | A | Stock Option (Right to Buy) | 35,234 | 15.90 | 560.2K | 35,234 | D | ↗ |
| 2025-05-01 | Girao Tiago | Officer | A-Award | A | Stock Option (Right to Buy) | 293,505 | 15.90 | 4.67M | 293,505 | D | ↗ |
| 2025-05-01 | Bauer Jake | Director | A-Award | A | Stock Option (Right to Buy) | 35,234 | 15.90 | 560.2K | 35,234 | D | ↗ |
| 2025-04-23 | Stout Jay S | Officer | S-Sale | D | Common Stock | 1,925 | 14.79 | 28.5K | 209,243 | D | ↗ |
| 2025-04-23 | Geffner Michael | Officer | S-Sale | D | Common Stock | 2,349 | 14.79 | 34.7K | 225,370 | D | ↗ |
| 2025-04-21 | Girao Tiago | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-18 | Susman Robert Graham | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-18 | Bauer Jake | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-16 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 8,321 | 14.89 | 123.9K | 1,178,191 | D | ↗ |
| 2025-04-16 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 2,993 | 14.89 | 44.6K | 396,774 | D | ↗ |
| 2025-04-09 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 28,094 | 12.99 | 364.9K | 1,186,512 | D | ↗ |
| 2025-04-01 | Van Tuyl Christopher | Officer | A-Award | A | Stock Option (right to buy) | 71,531 | 15.20 | 1.09M | 71,531 | D | ↗ |
| 2025-04-01 | Torti Frank | Director | A-Award | A | Common Stock | 199,365 | 0.00 | — | 835,039 | D | ↗ |
| 2025-04-01 | Stout Jay S | Officer | A-Award | A | Stock Option (right to buy) | 107,297 | 15.20 | 1.63M | 107,297 | D | ↗ |
| 2025-04-01 | Salzmann Peter | Director / Officer | A-Award | A | Common Stock | 265,820 | 0.00 | — | 1,214,606 | D | ↗ |
| 2025-04-01 | Pande Atul | Director | A-Award | A | Common Stock | 16,188 | 0.00 | — | 102,851 | D | ↗ |
| 2025-04-01 | MIGAUSKY GEORGE V | Director | A-Award | A | Common Stock | 16,188 | 0.00 | — | 137,251 | D | ↗ |
| 2025-04-01 | Hughes Douglas J. | Director | A-Award | A | Stock Option (right to buy) | 7,600 | 15.20 | 115.5K | 7,600 | D | ↗ |
| 2025-04-01 | Gloria Melanie | Officer | A-Award | A | Stock Option (right to buy) | 107,297 | 15.20 | 1.63M | 107,297 | D | ↗ |
| 2025-04-01 | Geffner Michael | Officer | A-Award | A | Stock Option (right to buy) | 143,063 | 15.20 | 2.17M | 143,063 | D | ↗ |
| 2025-04-01 | Fromkin Andrew J. | Director | A-Award | A | Stock Option (right to buy) | 7,600 | 15.20 | 115.5K | 7,600 | D | ↗ |
| 2025-04-01 | Barnett Eva Renee | Officer | A-Award | A | Stock Option (right to buy) | 125,180 | 15.20 | 1.90M | 125,180 | D | ↗ |
| 2025-03-07 | Fromkin Andrew J. | Director | S-Sale | D | Common Stock | 6,616 | 19.52 | 129.1K | 93,297 | D | ↗ |
| 2025-02-19 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 15,439 | 20.86 | 322.1K | 948,786 | D | ↗ |
| 2025-02-19 | Macias William L. | Officer | S-Sale | D | Common Stock | 2,055 | 20.86 | 42.9K | 357,353 | D | ↗ |
| 2025-02-19 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 2,814 | 20.86 | 58.7K | 321,952 | D | ↗ |
| 2025-01-22 | Stout Jay S | Officer | S-Sale | D | Common Stock | 2,195 | 23.59 | 51.8K | 139,991 | D | ↗ |
| 2025-01-22 | Geffner Michael | Officer | S-Sale | D | Common Stock | 2,657 | 23.59 | 62.7K | 132,314 | D | ↗ |
| 2025-01-15 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 8,352 | 23.81 | 198.9K | 964,640 | D | ↗ |
| 2025-01-15 | Macias William L. | Officer | S-Sale | D | Common Stock | 1,883 | 23.81 | 44.8K | 359,908 | D | ↗ |
| 2025-01-15 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 2,189 | 23.81 | 52.1K | 324,875 | D | ↗ |
| 2025-01-13 | Roivant Sciences Ltd. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 16,845,010 | 20.00 | 336.90M | 96,650,341 | D | ↗ |
| 2025-01-08 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 5,105 | 24.10 | 123.0K | 972,992 | D | ↗ |
| 2025-01-08 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 4,105 | 24.10 | 98.9K | 327,064 | D | ↗ |
| 2024-12-16 | Van Tuyl Christopher | Officer | A-Award | A | Stock Option (right to buy) | 137,446 | 27.63 | 3.80M | 137,446 | D | ↗ |
| 2024-12-02 | Pande Atul | Director | S-Sale | D | Common Stock | 7,750 | 28.54 | 221.2K | 86,663 | D | ↗ |
| 2024-12-02 | Hughes Douglas J. | Director | S-Sale | D | Common Stock | 5,425 | 28.54 | 154.8K | 119,585 | D | ↗ |
| 2024-11-20 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 16,692 | 25.45 | 424.8K | 978,097 | D | ↗ |
| 2024-11-20 | Macias William L. | Officer | S-Sale | D | Common Stock | 3,353 | 25.45 | 85.3K | 361,791 | D | ↗ |
| 2024-11-20 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 3,650 | 25.45 | 92.9K | 319,228 | D | ↗ |
| 2024-11-20 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 4,174 | 25.45 | 106.2K | 331,169 | D | ↗ |
| 2024-11-18 | Gloria Melanie | Officer | A-Award | A | Stock Option (right to buy) | 137,446 | 25.51 | 3.51M | 137,446 | D | ↗ |
| 2024-10-23 | Stout Jay S | Officer | S-Sale | D | Common Stock | 2,740 | 29.53 | 80.9K | 142,186 | D | ↗ |
| 2024-10-23 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 4,361 | 29.53 | 128.8K | 322,878 | D | ↗ |
| 2024-10-23 | Geffner Michael | Officer | S-Sale | D | Common Stock | 3,189 | 29.53 | 94.2K | 134,971 | D | ↗ |
| 2024-10-16 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 9,095 | 28.79 | 261.8K | 994,789 | D | ↗ |
| 2024-10-16 | Macias William L. | Officer | S-Sale | D | Common Stock | 561 | 28.79 | 16.2K | 365,144 | D | ↗ |
| 2024-10-16 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 2,860 | 28.79 | 82.3K | 327,239 | D | ↗ |
| 2024-10-16 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 3,271 | 28.79 | 94.2K | 335,343 | D | ↗ |
| 2024-10-09 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 4,460 | 29.56 | 131.8K | 1,003,884 | D | ↗ |
| 2024-10-09 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 5,162 | 29.56 | 152.6K | 338,614 | D | ↗ |
| 2024-08-21 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 598 | 32.32 | 19.3K | 1,008,344 | — | ↗ |
| 2024-08-21 | Macias William L. | Officer | S-Sale | D | Common Stock | 120 | 32.32 | 3.9K | 368,332 | — | ↗ |
| 2024-08-21 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 131 | 32.32 | 4.2K | 330,099 | — | ↗ |
| 2024-08-21 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 120 | 32.32 | 3.9K | 440,959 | — | ↗ |
| 2024-08-21 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 149 | 32.32 | 4.8K | 343,776 | — | ↗ |
| 2024-07-24 | Stout Jay S | Officer | S-Sale | D | Common Stock | 2,813 | 27.76 | 78.1K | 144,926 | — | ↗ |
| 2024-07-24 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 4,015 | 27.76 | 111.5K | 333,394 | — | ↗ |
| 2024-07-24 | Geffner Michael | Officer | S-Sale | D | Common Stock | 3,456 | 27.76 | 95.9K | 138,160 | — | ↗ |
| 2024-07-17 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 510 | 30.55 | 15.6K | 1,023,412 | — | ↗ |
| 2024-07-17 | Macias William L. | Officer | S-Sale | D | Common Stock | 504 | 29.64 | 14.9K | 371,390 | — | ↗ |
| 2024-07-17 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 147 | 30.55 | 4.5K | 337,409 | — | ↗ |
| 2024-07-17 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 169 | 30.55 | 5.2K | 443,986 | — | ↗ |
| 2024-07-17 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 2,939 | 29.64 | 87.1K | 347,728 | — | ↗ |
| 2024-07-09 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 4,619 | 28.06 | 129.6K | 1,032,097 | — | ↗ |
| 2024-07-09 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 1,527 | 28.06 | 42.8K | 446,853 | — | ↗ |
| 2024-07-09 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 4,747 | 28.06 | 133.2K | 350,667 | — | ↗ |
| 2024-05-22 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 16,163 | 29.65 | 479.2K | 1,036,716 | — | ↗ |
| 2024-05-22 | Macias William L. | Officer | S-Sale | D | Common Stock | 3,247 | 29.65 | 96.3K | 374,403 | — | ↗ |
| 2024-05-22 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 3,242 | 29.65 | 96.1K | 339,914 | — | ↗ |
| 2024-05-22 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 3,247 | 29.65 | 96.3K | 448,380 | — | ↗ |
| 2024-05-22 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 4,042 | 29.65 | 119.8K | 355,414 | — | ↗ |
| 2024-04-24 | Stout Jay S | Officer | S-Sale | D | Common Stock | 7,239 | 28.90 | 209.2K | 147,739 | — | ↗ |
| 2024-04-24 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 3,963 | 28.90 | 114.5K | 343,156 | — | ↗ |
| 2024-04-24 | Geffner Michael | Officer | S-Sale | D | Common Stock | 3,261 | 28.90 | 94.2K | 141,616 | — | ↗ |
| 2024-04-17 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 26,365 | 28.80 | 759.3K | 1,060,593 | — | ↗ |
| 2024-04-17 | Macias William L. | Officer | S-Sale | D | Common Stock | 6,136 | 28.80 | 176.7K | 379,794 | — | ↗ |
| 2024-04-17 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 7,602 | 28.80 | 218.9K | 349,344 | — | ↗ |
| 2024-04-17 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 7,825 | 28.80 | 225.4K | 453,917 | — | ↗ |
| 2024-04-17 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 9,479 | 28.80 | 273.0K | 362,230 | — | ↗ |
| 2024-04-09 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 4,807 | 31.18 | 149.9K | 1,086,958 | — | ↗ |
| 2024-04-09 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 1,053 | 31.18 | 32.8K | 461,742 | — | ↗ |
| 2024-04-09 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 3,689 | 31.18 | 115.0K | 371,709 | — | ↗ |
| 2024-04-02 | Torti Frank | Director | A-Award | A | Common Stock | 120,400 | 0.00 | — | 635,674 | — | ↗ |
| 2024-04-02 | Stout Jay S | Officer | A-Award | A | Stock Option (right to buy) | 68,723 | 30.78 | 2.12M | 68,723 | — | ↗ |
| 2024-04-02 | Salzmann Peter | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,667 | 30.78 | 6.18M | 200,667 | — | ↗ |
| 2024-04-02 | Pande Atul | Director | A-Award | A | Common Stock | 11,255 | 0.00 | — | 94,413 | — | ↗ |
| 2024-04-02 | Macias William L. | Officer | A-Award | A | Common Stock | 54,978 | 0.00 | — | 385,930 | — | ↗ |
| 2024-04-02 | MIGAUSKY GEORGE V | Director | A-Award | A | Stock Option (right to buy) | 4,690 | 30.78 | 144.4K | 4,690 | — | ↗ |
| 2024-04-02 | Levine Mark S. | Officer | A-Award | A | Common Stock | 54,978 | 0.00 | — | 356,946 | — | ↗ |
| 2024-04-02 | Hughes Douglas J. | Director | A-Award | A | Common Stock | 11,255 | 0.00 | — | 125,010 | — | ↗ |
| 2024-04-02 | Geffner Michael | Officer | A-Award | A | Stock Option (right to buy) | 68,723 | 30.78 | 2.12M | 68,723 | — | ↗ |
| 2024-04-02 | Fromkin Andrew J. | Director | A-Award | A | Common Stock | 11,255 | 0.00 | — | 99,913 | — | ↗ |
| 2024-04-02 | Butchko Julia G. | Officer | A-Award | A | Stock Option (right to buy) | 68,723 | 30.78 | 2.12M | 68,723 | — | ↗ |
| 2024-04-02 | Barnett Eva Renee | Officer | A-Award | A | Stock Option (right to buy) | 68,723 | 30.78 | 2.12M | 68,723 | — | ↗ |
| 2024-02-22 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 13,454 | 36.15 | 486.4K | 931,231 | — | ↗ |
| 2024-02-22 | Macias William L. | Officer | S-Sale | D | Common Stock | 2,221 | 36.15 | 80.3K | 330,952 | — | ↗ |
| 2024-02-22 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 2,134 | 36.15 | 77.1K | 301,968 | — | ↗ |
| 2024-02-22 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 2,146 | 36.15 | 77.6K | 407,817 | — | ↗ |
| 2024-02-22 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 2,930 | 36.15 | 105.9K | 320,420 | — | ↗ |
| 2024-01-26 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 2,981 | 37.91 | 113.0K | 304,148 | — | ↗ |
| 2024-01-26 | Geffner Michael | Officer | S-Sale | D | Common Stock | 9,948 | 37.91 | 377.1K | 90,052 | — | ↗ |
| 2024-01-18 | Macias William L. | Officer | S-Sale | D | Common Stock | 424 | 41.03 | 17.4K | 333,173 | — | ↗ |
| 2024-01-17 | Geffner Michael | Officer | — | D | Stock Option (right to buy) | 150,000 | 18.06 | 2.71M | 0 | — | ↗ |
| 2024-01-16 | Geffner Michael | Officer | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2024-01-11 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 2,681 | 41.64 | 111.6K | 324,184 | — | ↗ |
| 2024-01-05 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 3,824 | 38.59 | 147.6K | 944,685 | — | ↗ |
| 2024-01-05 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 1,297 | 38.59 | 50.1K | 409,963 | — | ↗ |
| 2023-12-01 | Pande Atul | Director | S-Sale | D | Common Stock | 3,374 | 39.82 | 134.4K | 88,005 | — | ↗ |
| 2023-12-01 | MIGAUSKY GEORGE V | Director | S-Sale | D | Common Stock | 5,022 | 40.46 | 203.2K | 109,808 | — | ↗ |
| 2023-12-01 | Fromkin Andrew J. | Director | S-Sale | D | Common Stock | 4,773 | 40.46 | 193.1K | 88,658 | — | ↗ |
| 2023-11-22 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 616 | 33.52 | 20.6K | 948,509 | — | ↗ |
| 2023-11-22 | Macias William L. | Officer | S-Sale | D | Common Stock | 124 | 33.52 | 4.2K | 333,597 | — | ↗ |
| 2023-11-22 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 3,128 | 32.75 | 102.4K | 307,253 | — | ↗ |
| 2023-11-22 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 3,141 | 32.75 | 102.9K | 411,384 | — | ↗ |
| 2023-11-22 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 154 | 33.52 | 5.2K | 326,865 | — | ↗ |
| 2023-10-25 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 4,107 | 34.66 | 142.3K | 310,381 | — | ↗ |
| 2023-10-19 | Macias William L. | Officer | S-Sale | D | Common Stock | 530 | 36.80 | 19.5K | 336,862 | — | ↗ |
| 2023-10-10 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 4,557 | 36.92 | 168.2K | 330,920 | — | ↗ |
| 2023-10-05 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 894 | 35.54 | 31.8K | 969,071 | — | ↗ |
| 2023-10-05 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 296 | 35.54 | 10.5K | 415,964 | — | ↗ |
| 2023-10-02 | Roivant Sciences Ltd. | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value per share | 1,526,316 | 38.00 | 58.00M | 79,805,331 | — | ↗ |
| 2023-08-30 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 50,866 | 21.97 | 1.12M | 975,873 | — | ↗ |
| 2023-08-24 | Macias William L. | Officer | S-Sale | D | Common Stock | 1 | 20.89 | 20.89 | 337,392 | — | ↗ |
| 2023-08-24 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 1 | 20.89 | 20.89 | 314,488 | — | ↗ |
| 2023-08-24 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 1 | 20.89 | 20.89 | 416,260 | — | ↗ |
| 2023-08-24 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 14,385 | 20.30 | 292.0K | 335,478 | — | ↗ |
| 2023-08-14 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 91,744 | 21.34 | 1.96M | 1,038,053 | — | ↗ |
| 2023-08-07 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 101,339 | 21.73 | 2.20M | 1,129,797 | — | ↗ |
| 2023-07-26 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 3,917 | 21.63 | 84.7K | 326,774 | — | ↗ |
| 2023-07-19 | Macias William L. | Officer | S-Sale | D | Common Stock | 426 | 24.94 | 10.6K | 349,725 | — | ↗ |
| 2023-07-19 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 2,725 | 24.94 | 68.0K | 349,863 | — | ↗ |
| 2023-07-12 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 3,233 | 19.73 | 63.8K | 1,231,136 | — | ↗ |
| 2023-07-12 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 1,470 | 19.73 | 29.0K | 428,593 | — | ↗ |
| 2023-04-25 | Macias William L. | Officer | S-Sale | D | Common Stock | 509 | 16.29 | 8.3K | 350,151 | — | ↗ |
| 2023-04-25 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 2,633 | 16.29 | 42.9K | 330,691 | — | ↗ |
| 2023-04-18 | Salzmann Peter | Director / Officer | S-Sale | D | Common Stock | 3,395 | 15.27 | 51.8K | 1,234,369 | — | ↗ |
| 2023-04-18 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 1,544 | 15.27 | 23.6K | 430,063 | — | ↗ |
| 2023-04-18 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 3,423 | 15.27 | 52.3K | 352,588 | — | ↗ |
| 2023-04-17 | Stout Jay S | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-12 | Torti Frank | Director | A-Award | A | Stock Option (right to buy) | 158,292 | 14.70 | 2.33M | 158,292 | — | ↗ |
| 2023-04-12 | Salzmann Peter | Director / Officer | A-Award | A | Stock Option (right to buy) | 316,585 | 14.70 | 4.65M | 316,585 | — | ↗ |
| 2023-04-12 | Pande Atul | Director | A-Award | A | Common Stock | 12,523 | 0.00 | — | 95,508 | — | ↗ |
| 2023-04-12 | Macias William L. | Officer | A-Award | A | Stock Option (right to buy) | 113,821 | 14.70 | 1.67M | 113,821 | — | ↗ |
| 2023-04-12 | MIGAUSKY GEORGE V | Director | A-Award | A | Stock Option (right to buy) | 16,260 | 14.70 | 239.0K | 16,260 | — | ↗ |
| 2023-04-12 | Levine Mark S. | Officer | A-Award | A | Stock Option (right to buy) | 113,821 | 14.70 | 1.67M | 113,821 | — | ↗ |
| 2023-04-12 | Hughes Douglas J. | Director | A-Award | A | Stock Option (right to buy) | 16,260 | 14.70 | 239.0K | 16,260 | — | ↗ |
| 2023-04-12 | Fromkin Andrew J. | Director | A-Award | A | Stock Option (right to buy) | 16,260 | 14.70 | 239.0K | 16,260 | — | ↗ |
| 2023-04-12 | Butchko Julia G. | Officer | A-Award | A | Common Stock | 100,188 | 0.00 | — | 431,607 | — | ↗ |
| 2023-04-12 | Barnett Eva Renee | Officer | A-Award | A | Stock Option (right to buy) | 113,821 | 14.70 | 1.67M | 113,821 | — | ↗ |
| 2023-02-02 | Macias William L. | Officer | S-Sale | D | Common Stock | 537 | 18.24 | 9.8K | 262,996 | — | ↗ |
| 2023-01-26 | Levine Mark S. | Officer | S-Sale | D | Common Stock | 10,156 | 18.51 | 188.0K | 245,660 | — | ↗ |
| 2023-01-11 | Salzmann Peter | Officer | S-Sale | D | Common Stock | 4,021 | 16.80 | 67.6K | 993,932 | — | ↗ |
| 2023-01-11 | Macias William L. | Officer | S-Sale | D | Common Stock | 120 | 15.11 | 1.8K | 307,981 | — | ↗ |
| 2023-01-11 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 60,471 | 16.79 | 1.02M | 331,419 | — | ↗ |
| 2023-01-11 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 11 | 15.15 | 166.65 | 272,846 | — | ↗ |
| 2022-10-21 | Macias William L. | Officer | S-Sale | D | Common Stock | 341 | 9.67 | 3.3K | 308,101 | — | ↗ |
| 2022-10-13 | Salzmann Peter | Officer | S-Sale | D | Common Stock | 2,793 | 9.18 | 25.6K | 997,953 | — | ↗ |
| 2022-10-13 | Butchko Julia G. | Officer | S-Sale | D | Common Stock | 928 | 9.18 | 8.5K | 391,909 | — | ↗ |
| 2022-10-11 | Barnett Eva Renee | Officer | S-Sale | D | Common Stock | 12,500 | 9.44 | 118.0K | 272,857 | — | ↗ |
| 2022-10-06 | Roivant Sciences Ltd. | Director | P-Purchase | A | Common Stock, $0.0001 par value per share | 416,667 | 6.00 | 2.50M | 73,805,331 | — | ↗ |
Executive team
Top executives
Shares Outstanding
205.31M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Peter Salzmann, M.D. Former Chief Executive Officer | 724.5K | 470.9K | 4.94M | 4.54M | — | 55.6K | 10.73M | 88.34% | ↗ |
| 2 | 2025 | Christopher Van Tuyl Chief Legal Officer and Corporate Secretary | 140.3K | 62.9K | 3.04M | 2.70M | — | 7.4K | 5.95M | 96.46% | ↗ |
| 3 | 2025 | Melanie Gloria Chief Operating Officer | 180.4K | 79.5K | 2.80M | 2.50M | — | 8.2K | 5.57M | 95.19% | ↗ |
| 4 | 2025 | Michael Geffner, M.D. Chief Medical Officer | 518.0K | 233.1K | 1.69M | 1.55M | — | 52.9K | 4.05M | 80.15% | ↗ |
| 5 | 2025 | Eva Renee Barnett Former Chief Financial Officer | 481.0K | 216.5K | 1.69M | 1.55M | — | 26.3K | 3.97M | 81.77% | ↗ |
| 6 | 2024 | Peter Salzmann, M.D., M.B.A. Chief Executive Officer | 700.0K | 609.0K | 3.58M | 3.62M | — | 39.4K | 8.55M | 84.23% | ↗ |
| 7 | 2024 | Peter Salzmann, M.D. Former Chief Executive Officer | 700.0K | 609.0K | 3.58M | 3.62M | — | 39.4K | 8.55M | 84.23% | ↗ |
| 8 | 2024 | Jay S. Stout, Ph.D. Chief Technology Officer | 416.9K | 241.9K | 1.55M | 1.81M | — | 24.7K | 4.04M | 83.08% | ↗ |
| 9 | 2024 | Julia G. Butchko, Ph.D. Chief Development Officer | 465.0K | 269.7K | 1.47M | 1.49M | — | 13.0K | 3.71M | 79.83% | ↗ |
| 10 | 2024 | Eva Renee Barnett Former Chief Financial Officer | 465.0K | 269.7K | 1.29M | 1.30M | — | 14.2K | 3.34M | 77.57% | ↗ |
| 11 | 2023 | Peter Salzmann, M.D., M.B.A. Chief Executive Officer | 625.0K | 360.9K | 2.25M | 2.54M | — | 37.8K | 5.82M | 82.41% | ↗ |
| 12 | 2023 | Peter Salzmann, M.D. Former Chief Executive Officer | 625.0K | 360.9K | 2.25M | 2.54M | — | 37.8K | 5.82M | 82.41% | ↗ |
| 13 | 2023 | Eva Renee Barnett, M.B.A. Chief Financial Officer | 435.0K | 414.4K | 563.0K | 636.1K | — | 21.6K | 2.07M | 57.92% | ↗ |
| 14 | 2023 | Eva Renee Barnett Former Chief Financial Officer | 435.0K | 414.4K | 563.0K | 636.1K | — | 21.6K | 2.07M | 57.92% | ↗ |
| 15 | 2023 | William L. Macias, M.D., Ph.D. Chief Medical Officer | 500.0K | 210.0K | 563.0K | 636.1K | — | 9.9K | 1.92M | 62.49% | ↗ |
| 16 | 2022 | William L. Macias, M.D., Ph.D. Chief Medical Officer | 219.2K | 94.6K | 961.9K | 1.14M | — | 4.41M | 6.82M | 30.84% | ↗ |
| 17 | 2022 | Peter Salzmann, M.D., M.B.A. Chief Executive Officer | 600.0K | 346.5K | 4.00M | 888.4K | — | 33.5K | 5.87M | 83.30% | ↗ |
| 18 | 2022 | Eva Renee Barnett, M.B.A. Chief Financial Officer | 198.5K | 328.0K | 1.77M | 2.13M | — | 8.5K | 4.43M | 87.92% | ↗ |
| 19 | 2021 | Peter Salzmann, M.D., M.B.A. Chief Executive Officer | 567.0K | 311.9K | 3.25M | 11.10M | — | 139.0K | 15.38M | 93.38% | ↗ |
| 20 | 2020 | Michael J. Elliott, M.B.B.S., Ph.D., FRACP Former Chief Scientific Officer | 242.4K | 96.0K | 1.66M | 14.23M | — | 9.7K | 16.24M | 97.86% | ↗ |
| 21 | 2020 | Peter Salzmann, M.D., M.B.A. Chief Executive Officer | 567.0K | 311.9K | 3.25M | 11.10M | — | 139.0K | 15.38M | 93.38% | ↗ |
| 22 | 2020 | Rita Jain, M.D. Former Chief Medical Officer | 101.1K | 38.5K | 2.70M | 10.67M | — | 3.3K | 13.51M | 98.94% | ↗ |
| 23 | 2020 | Julia G. Butchko, Ph.D. Chief Development and Technology Officer | 372.0K | 148.8K | 926.5K | 6.38M | — | 10.2K | 7.84M | 93.23% | ↗ |
| 24 | 2020 | Pamela Yanchik Connealy, M.B.A. Chief Financial Officer | 393.0K | 157.2K | 785.4K | 4.26M | — | 8.7K | 5.60M | 90.02% | ↗ |
| 25 | 2019 | Peter Salzmann, M.D., M.B.A. Chief Executive Officer | 361.0K | 500.0K | — | 7.72M | 224.5K | — | 8.81M | 87.67% | ↗ |
| 26 | 2019 | Robert K. Zeldin, M.D., FAAAAI Former Chief Medical Officer | 283.2K | 85.0K | — | 2.51M | — | — | 2.88M | 87.21% | ↗ |
| 27 | 2019 | Pamela Yanchik Connealy, M.B.A. Chief Financial Officer | 147.6K | — | — | 2.44M | 61.2K | 129.3K | 2.78M | 87.82% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tiago Girao | Chief Financial Officer | 871.1K | male |
| William L. Macias | CMO Emeritus | 719.9K | — |
| Jay S. Stout | Chief Technology Officer | 683.5K | — |
| Melanie Gloria | Chief Operating Officer | 575.9K | female |
| Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary | 549.0K | male |
| Frank Torti | Executive Chairperson of the Board | 92.5K | — |
| Eric Venker | Chief Executive Officer & Director | 55.0K | — |
| Yan Zheng | Senior Vice President of Biostatistics, Programming & Data Management | — | female |
| Becky Merlina | Senior VP & Global Head of Quality | — | female |
| Christine Blodgett | Senior Vice President of Human Resources | — | female |
| Julie Kirschling | Senior Vice President of Program & Alliance Management | — | female |
| Sheetal Patel | Senior Vice President of Clinical Development | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMVT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
